Skip to main content
Equibles
OCUL logo

OCUL · Ocular Therapeutix, Inc · Documents

Track OCUL — free

Use OCUL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OCUL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.14 +0.32 (+4.69%) At close · Nov 4 Play latest call Q1 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.54B
Shares
219.62M
Volume · Nov 4 3.36M Avg daily vol (3M) 3.04M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $51.95M down 18.5% 10-K filed Feb 5, 2026 Quarterly report FY2026 Q2 Revenue $13.48M up 0.1% 10-Q filed Aug 3, 2026 Latest results Financial results 8-K filed Aug 3, 2026 Earnings call Q1 2026 earnings call Held May 5, 2026
2026
Oct 16
Current report 8-K Events of Oct 14
Director or officer change, or executive pay

Ocular Therapeutix, Inc. reported that Sanjay Nayak, M.B.B.S., Ph.D., resigned as Chief Strategy Officer effective October 16, 2026 to become Chief Executive Officer of a privately-held company.

Aug 3
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $13.48M ▲ 0.1% Net loss $78.76M Diluted EPS -$0.35
May 5
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $10.79M ▲ 0.8% Net loss $88.61M Diluted EPS -$0.40
Apr 30
Proxy statement DEF 14A Meeting Jun 11, 2026
Proxy statement AI summary on its way
Feb 5
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $51.95M ▼ 18.5% Net loss $265.94M Diluted EPS -$1.42
2025
Mar 3
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $63.72M ▲ 9.0% Net loss $193.51M Diluted EPS -$1.22
2024
Showing 1–50 of 160 documents
Key facts CIK 1393434 CUSIP 67576A100 13F (30d) 65 filings 65 filers Visit website Investor relations